Actively Recruiting
Impact of Capillaroscopy in the Investigation of Diffuse Interstitial Pneumonias
Led by University Hospital, Bordeaux · Updated on 2026-03-20
48
Participants Needed
1
Research Sites
50 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The investigators hypothesize that in patients with a new diagnosis of Pulmonary Interstitial Disease (PID), adding capillaroscopy to standard care increases the proportion of patients receiving a diagnosis of PID-Connective Tissue Disease (PID-CTD) within the first three months of follow-up, thereby reducing the time to diagnosis and facilitating the implementation of appropriate treatment as quickly as possible. Therefore, To confirm this hypothesis, it is necessary to know the characteristics of capillaroscopy in patients with a new diagnosis of PID.
CONDITIONS
Official Title
Impact of Capillaroscopy in the Investigation of Diffuse Interstitial Pneumonias
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female over 18 years of age;
- Have received a new diagnosis of PID within the last six months, confirmed by a pulmonologist;
- Have undergone some specific tests within the last six months (Chest CT scan, respiratory function tests (plethysmography and CO transfer capacity measurement, immunological assessment including: screening for FAN, FR, and anti-CCP);
- French-speaking patient with no comprehension difficulties;
- Person affiliated with or beneficiary of a social security system;
- Free, informed, and written consent signed by the participant and the investigator (no later than the day of inclusion and before any examination required by the research).
You will not qualify if you...
- Have previously undergone a capillaroscopy, regardless of the reason;
- Have a diagnosis or high suspicion of connective tissue disease based on initial clinical and paraclinical evaluation;
- Have already started one of the following treatments for pulmonary involvement: systemic corticosteroids, immunosuppressive therapy, antifibrotic therapy;
- Pregnant or breastfeeding women;
- Patients covered by Articles L 1121-5 to L 1121-8 (persons deprived of their liberty by judicial or administrative decision, minors, adults subject to legal protection measures, or persons unable to give their consent).
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
CHU de Bordeaux - service de rhumatologie
Bordeaux, France
Actively Recruiting
Research Team
M
Marie-Elise TRUCHETET, MD, PhD
CONTACT
T
Thomas BARNETCHE, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here